Drugmakers announce new price increase due to shortage of 120 drugs

WSJ has published an article analyzing the drug shortage emergency recently arisen in the US. As many as 120 drugs currently have availability issues, due to the supply restrictions for some active ingredients from China and some major “product recalls” involving Israel-based Teva, Mylan and China-based Zheijang Pharmaceuticals.

This situation has resulted in price increases by multinationals such as Johnson and Johnson, Pfizer and Allergan, but also by smaller groups facing shortage of active ingredients necessary for their products. The molecules facing the most serious shortages are hydromorphone, painkiller hydrochloride and blood pressure medication valsartan.

(Source: WSJ)